Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma
Open accessThe DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
Pancreatic ductal adenocarcinoma ranks among the most lethal of human malignancies. Here, we assess the cooperative interactions of two signature mutations in mice engineered to sustain pancreas-specific Cre-mediated activation of a mutant Kras allele ( Kras G12D ) and deletion of a conditional Ink4a/Arf tumor suppressor allele. The phenotypic impact of Kras G12D alone was limited primarily to the development of focal premalignant ductal lesions, termed pancreatic intraepithelial neoplasias (PanINs), whereas the sole inactivation of Ink4a/Arf failed to produce any neoplastic lesions in the pancreas. In combination, Kras G12D expression and Ink4a/Arf deficiency resulted in an earlier appearance of PanIN lesions and these neoplasms progressed rapidly to highly invasive and metastatic cancers, resulting in death in all cases by 11 weeks. The evolution of these tumors bears striking resemblance to the human disease, possessing a proliferative stromal component and ductal lesions with a propensity to advance to a poorly differentiated state. These findings in the mouse provide experimental support for the widely accepted model of human pancreatic adenocarcinoma in which activated KRAS serves to initiate PanIN lesions, and the INK4A/ARF tumor suppressors function to constrain the malignant conversion of these PanIN lesions into lethal ductal adenocarcinoma. This faithful mouse model may permit the systematic analysis of genetic lesions implicated in the human disease and serve as a platform for the identification of early disease markers and for the efficient testing of novel therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These KRAS mutations are also found in the early stages of pancreatic ductal adenocarcinoma, preceding the appearance of senescence markers such as p53, CDKN2A and SMAD4196.”
From SenNet recommendations for detecting senescent cells in different tissues (2024) · cites this paper as [196]
Experimental — accuracy not yet measuredIn the citing paper
“In a mouse model, CDKN2A loss accelerated KRASG12D-driven tumor growth54.”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [54]
In the citing paper
“GEMMs with compound mutations that combine Kras mutation with the inactivation of tumor suppressor genes Cdkn2a and Tp53, or with the inactivation of the TGFβ-SMAD4 signaling pathway in the pancreas develop invasive and metastatic PDAC (74–76), thus validating the role of these tumor suppressor pathways in PDAC progression (4).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [74]
In the citing paper
“combined expression of oncogenic Kras coupled with the deletion or loss of function of Trp53, Cdkn2a, or Smad4 in the pancreas of mice readily leads to invasive PDAC29–32.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 2×
“…in line with the high degree of coincident mutations of these genes in human cancers and the role of Ink4a/Arf loss in facilitating the oncogenicity of activated Hras in vitro and in vivo (Serrano et al. 1996, 1997; Chin et al. 1997; Kamijo et al. 1997; Rozenblum et al. 1997; Ruas and Peters 1998).”
BackgroundAnalysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898
Self-citationZhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585 · cited 2×
“…in line with the high degree of coincident mutations of these genes in human cancers and the role of Ink4a/Arf loss in facilitating the oncogenicity of activated Hras in vitro and in vivo (Serrano et al. 1996, 1997; Chin et al. 1997; Kamijo et al. 1997; Rozenblum et al. 1997; Ruas and Peters 1998).”
BackgroundSelf-citationTumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521 · cited 1×
“Although ARF is a known activator of the p53 pathway (Kamijo et al. 1998; Pomerantz et al. 1998; Stott et al. 1998; Zhang et al. 1998) and its loss clearly attenuates the function of that critical tumor suppressor, more recent studies have demonstrated that ARF has p53-independent…”
BackgroundSelf-citationGu, G., Dubauskaite, J., & Melton, D. A. (2002) · Development · doi:10.1242/dev.129.10.2447 · Cited by 1,518
Ouelle, D. E., Zindy, F., Ashmun, R. A., & Sherr, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90214-7 · Cited by 1,485
Warshaw, A. L., & Castillo, C. F.-D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202133260706 · Cited by 1,198
Stott, F. J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.17.5001 · Cited by 1,167
Research works printed but not linked: 17
- 2003, Cancer Res., 63, 2005
- 1976, Cancer Res., 36, 2690
- 1990, Mol. Cell. Biol., 10, 1779
- 1992, Am. J. Pathol., 140, 1237
- 2003, Cancer Res., 63, 2016
- 2001, Cancer Res., 61, 4923
- 1994, Am. J. Pathol., 145, 1547
- 10.1002/(SICI)1098-2264(200004)27:4<358::AID-GCC4>3.0.CO;2-O · doi:10.1002/(sici)1098-2264(200004)27:4<358::aid-gcc4>3.0.co;2-o
- 10.1002/(SICI)1097-0142(19990415)85:8<1703::AID-CNCR9>3.0.CO;2-R · DOI
- 2001, Cancer J., 7, 242
- 1997, Cancer Res., 57, 2140
- 1997, Cancer Res., 57, 1731
- 1998, Biochim. Biophys. Acta, 1378, F115
- 1998, Cancer Res., 58, 4740
- 2000, Cancer Res., 60, 2002
- 1986, Jpn. J. Cancer Res., 77, 370
- 1994, Am. J. Pathol., 145, 671
Cited by
Items 201–300 of 999
Funahashi, H., Satake, M., Dawson, D., Huynh, N.-A., Reber, H. A., Hines, O. J., & Eibl, G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0970 · Cited by 116
“Further studies using LSL-KRAS;PDX-1-Cre mice treated for a longer time period or crossed on a Trp53- or Ink4a/Arf-deficient background, which accelerates pancreatic cancer development (19, 20), will elucidate whether the actual reduction of mPanIN-3 lesions ultimately decreases the incidence of frank invasive pancrea…”
MethodHyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis
Mo, L., Zheng, X., Huang, H.-Y., Shapiro, E., Lepor, H., Cordon-Cardo, C., Sun, T.-T., & Wu, X.-R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30062 · Cited by 116
Rebouissou, S., Hérault, A., Letouzé, É., Neuzillet, Y., Laplanche, A., Ofualuka, K., Maillé, P., Leroy, K., Riou, A., Lepage, M., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4017 · Cited by 122
Erstad, D. J., Sojoodi, M., Taylor, M. S., Ghoshal, S., Razavi, A. A., Graham‐O'Regan, K. A., Bardeesy, N. M., Ferrone, C. R., Lanuti, M. D., Caravan, P. D., et al. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.034793 · Cited by 132
“Other groups developed similar models with mutations in Ink4/Arf (also known as Cdkn2a), Muc1, Mist1 (also known as Bhlha15), Smad4 and Tgfbr2 tumor suppressors (Aguirre et al., 2003; Tinder et al., 2008; Tuveson et al., 2006; Kojima et al., 2007; Ijichi et al., 2006).”
MethodSelf-citationQian, J., Niu, J., Li, M., Chiao, P. J., & Tsao, M.-S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3208 · Cited by 115
Hong, T. S., Ryan, D. P., Borger, D. R., Blaszkowsky, L. S., Yeap, B. Y., Ancukiewicz, M., Deshpande, V., Shinagare, S. A., Wo, J. Y.-L., Boucher, Y., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.03.034 · Cited by 116
Kras as a key oncogene and therapeutic target in pancreatic cancer
Collins, M. A., & di Magliano, M. P. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2013.00407 · Cited by 132
“Based on the observation that tumor suppressor genes are usually lost or inactivated in the human disease, KC mice have been crossed with loss-of-function or mutant allele for Ink4a (Aguirre et al., 2003) or p53 (Hingorani et al., 2005).”
BackgroundMazur, P. K., & Siveke, J. T. (2012) · Gut · doi:10.1136/gutjnl-2011-300756 · Cited by 112
“Conditional loss of the Ink4a/Arf locus in the Pdx1-Cre;Kras model led to acceleration of PanIN development, a greatly reduced tumour latency with an increase in undifferentiated and anaplastic PDAC, which showed micrometastasis to liver and lung.(11) Mice with conditional loss or dominant-negative mutations in the p5…”
BackgroundReichert, M., Takano, S., von Burstin, J., Kim, S.-B., Lee, J.-S., Ihida-Stansbury, K., Hahn, C., Heeg, S., Schneider, G., Rhim, A. D., et al. (2013) · Genes & Development · doi:10.1101/gad.204453.112 · Cited by 112
“2008); and (3) Pdx1-Cre;LSLKras mice aged 10 and 20 wk (termed KrasG12D) that harbor PanIN lesions and a subset develop PDAC (Aguirre et al. 2003; Hingorani et al. 2003, 2005).”
BackgroundRay, K. C., Bell, K. M., Yan, J., Gu, G., Chung, C. H., Washington, M. K., & Means, A. L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016786 · Cited by 111
“. When combined with loss of tumor suppressor genes, these PanIN lesions progress to invasive and metastatic PDAC”
BackgroundEpithelial and stromal co-evolution and complicity in pancreatic cancer
Hingorani, S. R. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00530-w · Cited by 108
CD4+ T lymphocyte ablation prevents pancreatic carcinogenesis in mice
Zhang, Y., Yan, W., Mathew, E., Bednar, F., Wan, S., Collins, M. A., Evans, R. A., Welling, T. H., Vonderheide, R. H., & di Magliano, M. P. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0016-t · Cited by 102
“the vast majority of human pancreatic cancers (11, 12), it is also found in a high percentage of PanIN (13, 14); studies inmice have validated thenotion that the presence ofmutantKras is required to initiate pancreatic carcinogenesis (15, 16).”
Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine
Knudsen, E. S., O’Reilly, E. M., Brody, J. R., & Witkiewicz, A. K. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.08.056 · Cited by 107
Grapin‐Botton, A. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.07.010 · Cited by 118
Minas, T. Z., Surdez, D., Javaheri, T., Tanaka, M., Howarth, M., Kang, H., Han, J. J., Han, Z., Sax, B., Kream, B. E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9388 · Cited by 115
Translating complexity and heterogeneity of pancreatic tumor: 3D in vitro to in vivo models
Heinrich, M. A., Mostafa, A. M. R. H., Morton, J. P., Hawinkels, L. J. A. C., & Prakash, J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.018 · Cited by 126
Guillot, J., Dominici, C., Lucchesi, A., Nguyen, H., Puget, A., Hocine, M., Rangel‐Sosa, M. M., Simic, M., Nigri, J., Guillaumond, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29659-w · Cited by 125
Targeting KRAS in pancreatic cancer: new drugs on the horizon
Bannoura, S. F., Uddin, M. H., Nagasaka, M., Fazili, F., Hallak, M. N. A., Philip, P. A., El‐Rayes, B. F., & Azmi, A. S. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09990-2 · Cited by 122
Yamamoto, K., Tateishi, K., Kudo, Y., Sato, T., Yamamoto, S., Miyabayashi, K., Matsusaka, K., Asaoka, Y., Ijichi, H., Hirata, Y., et al. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu136 · Cited by 114
Shingu, T., Ho, A. L., Yuan, L., Zhou, X., Dai, C., Zheng, S., Wang, Q., Zhong, Y., Chang, Q., Horner, J. W., et al. (2017) · Nature Genetics · doi:10.1038/ng.3711 · Cited by 103
Self-citationDirect reprogramming by oncogenic Ras and Myc
Ischenko, I., Zhi, J., Moll, U. M., Nemajerová, A., & Petrenko, O. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219592110 · Cited by 102
Chen, N., Singh, G., König, A. O., Liou, G., Störz, P., Zhang, J., Regul, L., Nagarajan, S., Kühnemuth, B., Johnsen, S. A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.01.033 · Cited by 108
A Hypusine–eIF5A–PEAK1 Switch Regulates the Pathogenesis of Pancreatic Cancer
Fujimura, K., Wright, T., Strnádel, J., Kaushal, S., Metildi, C. A., Lowy, A. M., Bouvet, M., Kelber, J. A., & Klemke, R. L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1031 · Cited by 102
“are the primary oncogenic drivers in human PDAC (29, 37).”
BackgroundAguilera, K. Y., Rivera, L. B., Hur, H., Carbon, J. G., Toombs, J. E., Goldstein, C. D., Dellinger, M. T., Castrillon, D. H., & Brekken, R. A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2800 · Cited by 100
“Concordantly, PDAs arise in the KIC model with short latency, are desmoplastic and lethal (19, 24, 32).”
KRAS/NF-κB/YY1/miR-489 Signaling Axis Controls Pancreatic Cancer Metastasis
Yuan, P., He, X.-H., Rong, Y., Cao, J., Li, Y., Hu, Y.-P., Liu, Y., Li, D., Lou, W., & Liu, M. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1898 · Cited by 102
PDX1 dynamically regulates pancreatic ductal adenocarcinoma initiation and maintenance
Roy, N., Takeuchi, K. K., Ruggeri, J. M., Bailey, P., Chang, D., Li, J., Leonhardt, L., Puri, S., Hoffman, M. T., Gao, S., et al. (2016) · Genes & Development · doi:10.1101/gad.291021.116 · Cited by 99
“Mouse models expressing oncogenic Kras throughout the pancreatic parenchyma faithfully recapitulate the human disease with PanIN formation and progression to adenocarcinoma (Aguirre et al. 2003; Hingorani et al. 2003, 2005).”
BackgroundQiu, W., Sahin, F., Iacobuzio-Donahue, C. A., Garcia-Carracedo, D., Wang, W. M., Kuo, C.-Y., Chen, D., Arking, D. E., Lowy, A. M., Hruban, R. H., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.357 · Cited by 99
“This mouse strain is distinct from the previously reported p16/p19 knockout strains [18, 21].”
InfluentialCell Intrinsic Role of COX-2 in Pancreatic Cancer Development
Hill, R., Li, Y., Tran, L. M., Dry, S., Calvopina, J. H., Garcia, A., Kim, C., Wang, Y., Donahue, T. R., Herschman, H. R., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0342 · Cited by 99
“in human PDAC, including loss of Ink4a/Arf (24), TGF-β receptor type 2 (Tgfbr2) (25),”
Smac Mimetic Increases Chemotherapy Response and Improves Survival in Mice with Pancreatic Cancer
Dineen, S. P., Roland, C. L., Greer, R., Carbon, J. G., Toombs, J. E., Gupta, P., Bardeesy, N., Sun, H., Williams, N., Minna, J. D., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3892 · Cited by 99
“p48-Cre: Kras: Ink4a/Arf lox/lox mice (14, 15) were genotyped shortly after birth, and therapy with saline, gemcitabine (25 mg/kg), or JP1201 (6 mg/kg) combined with gemcitabine was delivered by i.”
MethodInfluentialSelf-citationCancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment
Polireddy, K., & Chen, Q. (2016) · Journal of Cancer · doi:10.7150/jca.14922 · Cited by 119
“P16/CDKN2A cooperated with K-Ras in the development of PDAC (15).”
BackgroundUsing Genetically Engineered Mouse Models of Cancer to Aid Drug Development: An Industry Perspective
Singh, M., & Johnson, L. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0437 · Cited by 102
Extrinsic KRAS signaling shapes the pancreatic microenvironment through fibroblast reprogramming
Velez-Delgado, A., Donahue, K. L., Brown, K. L., Du, W., Irizarry-Negron, V., Menjivar, R. E., Lasse Opsahl, E. L., Steele, N. G., The, S., Lazarus, J., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.02.016 · Cited by 91
“Two of the most common Cre drivers include the Pancreatic and Duodenal Homeobox 1 (Pdx1) promoter (Pdx1-Cre;KrasLSL-G12D/þ) and insertion into the Pancreas Associated Transcription Factor 1a (Ptf1a) locus (Ptf1aCre/þ;KrasLSL-G12D/þ); both of these models are commonly referred to as KC.(6,7) Different precursor lesions…”
BackgroundMolecular mechanisms of pancreatic carcinogenesis
Furukawa, T., Sunamura, M., & Horii, A. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2005.00134.x · Cited by 96
Development of an Orthotopic Model of Invasive Pancreatic Cancer in an Immunocompetent Murine Host
Tseng, W. W., Winer, D. A., Kenkel, J. A., Choi, O., Shain, A. H., Pollack, J. R., French, R., Lowy, A. M., & Engleman, E. G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2384 · Cited by 93
“Other groups have shown that mutant Kras in combination with other targeted genetic mutations, including Ink4a/Arf and MUC1, can also accelerate the development and progression of pancreatic cancer (15, 16).”
BackgroundJonckheere, N., Skrypek, N., & SEUNINGEN, I. V. (2010) · Cancers · doi:10.3390/cancers2041794 · Cited by 114
“These models develop spontaneously pancreatic adenocarcinoma and faithfully recapitulate the PanIN sequence and therefore provide outstanding pathological study models [95-98].”
BackgroundJu, H., Ying, H., Tian, T., Ling, J., Fu, J., Yu, L., Wu, M., Yang, L., Achreja, A., Chen, G., et al. (2017) · Nature Communications · doi:10.1038/ncomms14437 · Cited by 105
Self-citationNerves and Pancreatic Cancer: New Insights into A Dangerous Relationship
Gasparini, G., Pellegatta, M., Crippa, S., Lena, M. S., Belfiori, G., Doglioni, C., Taveggia, C., & Falconi, M. (2019) · Cancers · doi:10.3390/cancers11070893 · Cited by 107
“Similarly, the KIC mouse model (Pdx1–Cre; LSL–KrasG12D/+; Ink4Af/f) [77] was used to study neural pl ticity in resp nse o PDAC and its microenvironm nt [78].”
BackgroundMethodInfluentialYuan, M., Tu, B., Li, H., Pang, H., Zhang, N., Fan, M., Bai, J., Wang, W., Shu, Z., DuFort, C. C., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00426-6 · Cited by 106
Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation
Robinson, J. P., VanBrocklin, M. W., Guilbeault, A. R., Signorelli, D. L., Brandner, S., & Holmen, S. L. (2009) · Oncogene · doi:10.1038/onc.2009.333 · Cited by 99
“We also thank Eric Holland, Martin McMahon, and Ronald DePinho for the reagents.”
MethodSomatic Mutations in Exocrine Pancreatic Tumors: Association with Patient Survival
Rachakonda, P. S., Bauer, A. S., Xie, H., Campa, D., Rizzato, C., Canzian, F., Beghelli, S., Greenhalf, W., Costello, E., Schanne, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060870 · Cited by 93
“The ‘classical’ PDAC categorized as KRAS dependent were shown to be potentially amenable to the directed therapy [2,23].”
InfluentialImpact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
Yousef, A., Yousef, M., Chowdhury, S., Abdilleh, K., Knafl, M., Edelkamp, P., Alfaro-Munoz, K., Chacko, R., Peterson, J., Smaglo, B. G., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00505-0 · Cited by 93
Bai, J., Liu, T., Tu, B., Yuan, M., Shu, Z., Fan, M., Huo, S., Guo, Y., Wang, L., Wang, H., et al. (2022) · Autophagy · doi:10.1080/15548627.2022.2093026 · Cited by 104
“Primary mouse PDAC lines 15,376 T used in this study was isolated as described [31] from genetically engineered C57BL/6 mice [18] (tetO_LKRAS TRP53/p53 PTF1A/p48-Cre), and maintained in DMEM medium containing 10% FBS and 1 μg/mL doxycycline.”
MethodAcute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss
Medyouf, H., Gao, X., Armstrong, F., Gusscott, S., Liu, Q., Gedman, A. L., Matherly, L. H., Schultz, K. R., Pflumio, F., You, M. J., et al. (2009) · Blood · doi:10.1182/blood-2009-04-214718 · Cited by 99
Nagaraju, G. P., Zhu, S., Wen, J., Farris, A. B., Adsay, V. N., Diaz, R., Snyder, J. P., Shoji, M., & El‐Rayes, B. F. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.08.002 · Cited by 91
“In transgenic mice models, silencing of p16 and activation of Ras are sufficient to promote spontaneous development of pancreatic cancer [21].”
BackgroundTransforming growth factor-β pathway: Role in pancreas development and pancreatic disease
Rane, S. G., Lee, J., & LIN, H. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.003 · Cited by 98
“Although, loss of p16 function in mice does not increase the susceptibility to pancreas cancer [77,78], it was recently shown that in cooperation with an activated ras oncogene, loss of p16 function increases susceptibility to pancreas cancer [79].”
BackgroundKonishi, H., Karakas, B., Abukhdeir, A. M., Lauring, J., Gustin, J. P., Garay, J. P., Konishi, Y., Gallmeier, E., Bachman, K. E., & Park, B. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0108 · Cited by 89
Cano, C. E., Sandí, M. J., Hamidi, T., Calvo, E. L., Turrini, O., Bartholin, L., Loncle, C., Secq, V., Garcia, S., Lomberk, G., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201201255 · Cited by 89
Drummond, C. J., Hanna, J. A., Garcia, M. R., Devine, D. J., Heyrana, A. J., Finkelstein, D., Rehg, J. E., & Hatley, M. E. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.12.001 · Cited by 108
“129S4-Krastm4Tyj/J Jackson Laboratories (Jackson et al., 2001) Cat # 8179 RID:IMSR_JAX:008179 Mouse: Cdkn2aflox/flox (Aguirre et al., 2003) Oligonucleotides SYBR primers for real-time PCR – see Table S6 Taqman FAM Probe – Gli1 ThermoFisher Cat # Mm00494654_m1 Taqman FAM Probe – MyoG ThermoFisher…”
BackgroundInfluentialWang, W., Friedland, S. C., Guo, B., O’Dell, M. R., Alexander, W. B., Whitney-Miller, C. L., Agostini-Vulaj, D., Huber, A. R., Myers, J. R., Ashton, J. M., et al. (2019) · Gut · doi:10.1136/gutjnl-2017-315541 · Cited by 88
Javadrashid, D., Baghbanzadeh, A., Derakhshani, A., Leone, P., Silvestris, N., Racanelli, V., Solimando, A. G., & Baradaran, B. (2021) · Biomedicines · doi:10.3390/biomedicines9040373 · Cited by 104
“P16/CDKN2A and oncogenic K-Ras expression co-exist alongside other aging markers, whereas in pancreatic cancer, the expression of P16/CDKN2A and markers are omitted [22].”
BackgroundNF1 Deletion Generates Multiple Subtypes of Soft-Tissue Sarcoma That Respond to MEK Inhibition
Dodd, R. D., Mito, J. K., Eward, W. C., Chitalia, R., Sachdeva, M., Ma, Y., Barretina, J., Dodd, L. G., & Kirsch, D. G. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0189 · Cited by 97
“The NF1 mice (11) and Ink4a/Arf mice (26) have been previously reported.”
BackgroundKRAS, YAP, and obesity in pancreatic cancer: A signaling network with multiple loops
Eibl, G., & Rozengurt, E. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.10.007 · Cited by 85
“in the Trp53 tumor suppressor gene, greatly accelerates PDAC development [23,28].”
BackgroundCo-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us
Tekle, G. E., Bernasocchi, T., Unni, A. M., Bertoni, F., Rossi, D., Rubin, M. A., & Theurillat, J.-P. P. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.04.009 · Cited by 93
Danilov, A. V., Neupane, D., Nagaraja, A. S., Feofanova, E. V., Humphries, L. A., DiRenzo, J., & Korc, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026815 · Cited by 91
“[3,4].”
Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer
Miranda, E., Destro, A., Malesci, A., Balladore, E., Bianchi, P. P., Baryshnikova, E., Franchi, G., Morenghi, E., Laghi, L., Gennari, L., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603337 · Cited by 94
“…that epithelial cells with activated Ras signalling require the cooperation of other signalling pathway to became metastogenic (Grunert et al, 2003) and the oncogenic Ras is thought to cooperates with several other proto-oncogenes such as p53 and p16INK4A (Serrano et al, 1996; Aguirre et al, 2003).”
BackgroundAgbunag, C., & Bar-Sagi, D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0807 · Cited by 85
“An increase in K-ras levels, principally through gene amplification mechanisms, has been also observed in advanced stages of PDA in humans, as well as in mouse models (7, 18).”
BackgroundTargeted Nanogels: A Versatile Platform for Drug Delivery to Tumors
Murphy, E. A., Majeti, B. K., Mukthavaram, R., Acevedo, L. M., Barnes, L. A., & Cheresh, D. A. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0729 · Cited by 94
“R40P cells were isolated and cultured from a spontaneous pancreatic tumor in Pdx1-Cre, LSLKRas, Ink4a/Arfmice after 7 weeks; both the mice and tumor cell isolation procedure were described previously (18, 19).”
MethodDuctal Pancreatic Cancer in Humans and Mice
TUVESON, D. A., & HINGORANI, S. R. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.040 · Cited by 85
Self-citationNovel therapeutic targets for pancreatic cancer
Tang, S.-C., & Chen, Y.-C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i31.10825 · Cited by 88
Oncogene activation in melanocytes links reactive oxygen to multinucleated phenotype and senescence
Leikam, C., Hufnagel, A., Schartl, M., & Meierjohann, S. (2008) · Oncogene · doi:10.1038/onc.2008.323 · Cited by 94
“Even though the link between oncogenic RAS or B-RAF and downstream senescence inducers in melanocytes is unclear, a connection between mitogen activated protein kinase (MAPK) activation and INK4A or ARF has been reported for other cell lines (Aguirre et al., 2003; Lachat et al., 2004; Michaloglou et al., 2005).”
BackgroundMurakami, S., Nemazanyy, I., White, S. M., Chen, H., Nguyen, C. D. K., Graham, G. T., Saur, D., Pende, M., & Yi, C. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.07.022 · Cited by 83
Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer
Klomp, J. E., Diehl, J. N., Klomp, J. A., Edwards, A. C., Yang, R., Morales, A. J., Taylor, K. E., Drizyte-Miller, K., Bryant, K. L., Schaefer, A., et al. (2024) · Science · doi:10.1126/science.adk0850 · Cited by 83
“%) as KRAS and is required for PDAC progression in mouse models ( 1 , 54 ).”
BackgroundMcIntyre, C. A., Grimont, A., Park, J., Meng, Y., Sisso, W. J., Seier, K. P., Jang, G. H., Walch, H. S., Aveson, V. G., Falvo, D. J., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.08.002 · Cited by 97
Nam, G.-H., Kwon, M., Jung, H., Ko, E., Kim, S. A., Choi, Y., Song, S. J., Kim, S., Lee, Y., Kim, G. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002474 · Cited by 82
“Importantly, the ternary combination treat-ment of simvastatin, oxaliplatin, and anti-PD-1 antibodies dramatically suppressed tumor growth and improved the survival rate of CT26 tumor-bearing mice (figure 6F,G).”
LaConti, J. J., Shivapurkar, N., Preet, A., Mays, A. D., Peran, I., Kim, S. E., Marshall, J. L., Riegel, A. T., & Wellstein, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020687 · Cited by 86
“The mutant Kras–driven pancreatic cancer model has been well characterized at numerous molecular and biological levels [35,36,37,38,39].”
BackgroundKRAS-driven model of Gorham-Stout disease effectively treated with trametinib
Sepehr, N. H., McCarter, A., Helaers, R., Galant, C., Boon, L. M., Brouillard, P., Vikkula, M., & Dellinger, M. T. (2021) · JCI Insight · doi:10.1172/jci.insight.149831 · Cited by 88
“We decided to use the Kraswt/LSL-G12D strain, because it has been widely used by others to generate genetically engineered mouse models of diseases caused by hyperactive KRAS signaling, such as lung adenocarcinoma and pancreatic ductal adenocarcinoma (13, 14).”
The promise of genetically engineered mice for cancer prevention studies
Green, J. E., & Hudson, T. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1565 · Cited by 92
Precursor lesions in pancreatic cancer: morphological and molecular pathology
Scarlett, C. J., Salisbury, E., Biankin, A. V., & Kench, J. G. (2011) · Pathology · doi:10.1097/pat.0b013e3283445e3a · Cited by 94
Fujimura, K., Choi, S., Wyse, M. M., Strnádel, J., Wright, T., & Klemke, R. L. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.687418 · Cited by 87
In vivo cation exchange in quantum dots for tumor-specific imaging
Liu, X., Braun, G. B., Qin, M., Ruoslahti, E. I., & Sugahara, K. N. (2017) · Nature Communications · doi:10.1038/s41467-017-00153-y · Cited by 82
Dormant Cancer Cells Contribute to Residual Disease in a Model of Reversible Pancreatic Cancer
Lin, W.-C., Rajbhandari, N., Liu, C., Sakamoto, K., Zhang, Q., Triplett, A. A., Batra, S. K., Opavsky, R., Felsher, D. W., DiMaio, D. J., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2067 · Cited by 81
Short-term gain, long-term pain: the senescence life cycle and cancer
Chan, A. S. L., & Narita, M. (2019) · Genes & Development · doi:10.1101/gad.320937.118 · Cited by 80
Khalaileh, A., Dreazen, A., Khatib, A., Apel, R., Swisa, A., Kidess-Bassir, N., Maitra, A., Meyuhas, O., Dor, Y., & Zamir, G. A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2014 · Cited by 94
“Additional hits such as genetic deficiency for Ink4A (7) or p53 (9) cause the formation of metastatic PDAC, recapitulating human pathology and lend-”
Lanfredini, S., Thapa, A., & O’Neill, E. E. (2019) · Biochemical Society Transactions · doi:10.1042/bst20170521 · Cited by 87
Kinsey, C., Balakrishnan, V., O’Dell, M. R., Huang, J. L., Newman, L., Whitney-Miller, C. L., Hezel, A. F., & Land, H. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.061 · Cited by 80
“Analysis of human PDA pathological precursors, together with studies in genetically engineeredmice, have established activating RAS mutations as a critical early events in PDA pathogenesis with cooperating loss of tumor suppressors genes occurring later (Aguirre et al., 2003; Bardeesy et al., 2006a; Hingorani et al.,…”
BackgroundMolecular mechanism of pancreatic cancer—understanding proliferation, invasion, and metastasis
Mihaljević, A. L., Michalski, C. W., Friess, H., & Kleeff, J. H. (2010) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-010-0622-5 · Cited by 98
“This process can be accelerated if these mice are crossed with the appropriate tumor suppressor background [33, 34].”
BackgroundIkenoue, T., Terakado, Y., Nakagawa, H., Hikiba, Y., Fujii, T., Matsubara, D., Noguchi, R., Zhu, C., Yamamoto, K., Kudo, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep23899 · Cited by 90
Notch and Kras in pancreatic cancer: At the crossroads of mutation, differentiation and signaling
De La O, J.-P., & Murtaugh, L. C. (2009) · Cell Cycle · doi:10.4161/cc.8.12.8744 · Cited by 79
Krasinskas, A. M., Moser, A. J., Saka, B., Adsay, V. N., & Chiosea, S. I. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.71 · Cited by 80
Pancreatic cancer cachexia: three dimensions of a complex syndrome
Kordes, M., Larsson, L., Engstrand, L., & Löhr, M. J. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01301-4 · Cited by 91
A quantitative analysis of the sensory and sympathetic innervation of the mouse pancreas
Lindsay, T. H., Halvorson, K. G., Peters, C. M., Ghilardi, J. R., Kuskowski, M. A., Wong, G. Y., & Mantyh, P. W. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2005.10.055 · Cited by 84
Whipple, C. A., Young, A. L., & Korc, M. (2011) · Oncogene · doi:10.1038/onc.2011.430 · Cited by 80
“The LSL-Kras mouse, which we combined with the loss of both GPC1 and INK4A, carries an oncogenic Kras (Kras) allele that has been knocked-in within its own locus but which is transcriptionally silenced by the insertion of a LoxP-Stop-LoxP element (LSL) located upstream of the transcriptional start site (Aguirre et al.…”
InfluentialGarcia, P. L., Miller, A. L., & Yoon, K. J. (2020) · Cancers · doi:10.3390/cancers12051327 · Cited by 77
“For example, a conditional loss of the INK4a/ARF (CDKN2A) locus generated more rapid development of PanIN lesions, decreased tumor latency, a more undifferentiated histology, and the dissemination of metastatic lesions to the liver and lungs in the LSL-KRASG12D background [59,60].”
BackgroundRare codons capacitate Kras-driven de novo tumorigenesis
Pershing, N. L. K., Lampson, B. L., Belsky, J. A., Kaltenbrun, E., MacAlpine, D. M., & Counter, C. M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77627 · Cited by 77
Genetic Progression of Pancreatic Cancer
Cowan, R. W., & Maitra, A. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000011 · Cited by 77
Carrière, C., Young, A. L., Gunn, J. R., Longnecker, D. S., & Korc, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027725 · Cited by 77
“Immunostaining procedures were as described previously [5].”
MethodRachagani, S., Senapati, S., Chakraborty, S., Ponnusamy, M. P., Kumar, S., Smith, L. M., Jain, M., & Batra, S. K. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.31 · Cited by 77
“1043 British Journal of Cancer (2011) 104(6), 1038 – 1048& 2011 Cancer Research UK G e n e ti c s a n d G e n o m ic s its metastasis (Aguirre et al, 2003; Hingorani et al, 2005; Bardeesy et al, 2006; Hezel et al, 2006).”
BackgroundInfluentialPysz, M. A., Machtaler, S., Seeley, E. S., Lee, J. J., Brentnall, T. A., Rosenberg, J., Tranquart, F., & Willmann, J. K. (2014) · Radiology · doi:10.1148/radiol.14140568 · Cited by 76
Senescence-associated SIN3B promotes inflammation and pancreatic cancer progression
Rielland, M., Cantor, D. J., Graveline, R., Hajdu, C., Mara, L., de Diego Diaz, B., Miller, G., & David, G. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72619 · Cited by 76
“Histologic examination of additional animals at different time points revealed PanIN surrounded by extensive fibrosis as early as 6 to 8 weeks and progressively higher grade lesions in Sin3Bp+/– KRaspG12D mice (Figure 1B), as previously reported (2).”
Mahadevan, K. K., LeBleu, V. S., Ramirez, E. V., Chen, Y., Li, B., Sockwell, A. M., Gagea, M., Sugimoto, H., Sthanam, L. K., Tampe, D., et al. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.07.025 · Cited by 73
Self-citationRas-Induced Senescence and its Physiological Relevance in Cancer
DiMauro, T., & David, G. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910793357998 · Cited by 76
Walters, D. M., Stokes, J. B., Adair, S. J., Stelow, E. B., Borgman, C. A., Lowrey, B. T., Xin, W., Blais, E. M., Lee, J. K., Papin, J. A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077065 · Cited by 81
“Due to these limitations, several in vivo models have been developed [7], including genetically engineered murine models which have been engineered with mutations in KRAS plus deletions or mutations in P53 [8], P16INK4 [9], MIST [10], SMAD4 [11], or TGFb [12].”
BackgroundCarrière, C., Gore, A. J., Norris, A. M., Gunn, J. R., Young, A. L., Longnecker, D. S., & Korc, M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.05.041 · Cited by 76
YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma
Tu, B., Yao, J., Ferri-Borgogno, S., Zhao, J., Chen, S., Wang, Q., Yan, L., Zhou, X., Zhu, C., Bang, S., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.130811 · Cited by 75
Metastasis in Pancreatic Ductal Adenocarcinoma: Current Standing and Methodologies
Pereira, M. A., & Chio, I. I. C. (2019) · Genes · doi:10.3390/genes11010006 · Cited by 94
Ketogenic HMG‐CoA lyase and its product β‐hydroxybutyrate promote pancreatic cancer progression
Gouirand, V., Gicquel, T., Lien, E. C., Jaune, E., Costa, Q. D., Finetti, P., Metay, E., Duluc, C., Mayers, J. R., Audebert, S., et al. (2022) · The EMBO Journal · doi:10.15252/embj.2021110466 · Cited by 78
Dissecting metastasis using preclinical models and methods
Hebert, J. D., Neal, J. W., & Winslow, M. M. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00568-4 · Cited by 86
Epithelial cell senescence: an adaptive response to pre-carcinogenic stresses?
Abbadie, C., Pluquet, O., & Pourtier, A. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2587-9 · Cited by 82
A modular and flexible ESC-based mouse model of pancreatic cancer
Saborowski, M., Saborowski, A., Morris, J. P., Bosbach, B., Dow, L. E., Pelletier, J., Klimstra, D. S., & Lowe, S. W. (2014) · Genes & Development · doi:10.1101/gad.232082.113 · Cited by 75
“…Cre recombinase recapitulate all of these histological characteristics (Hingorani et al. 2003), and models that incorporate additional relevant lesions such as p53 mutations show accelerated disease onset and metastasis (Aguirre et al. 2003; Hingorani et al. 2005; Bardeesy et al. 2006a,b).”
BackgroundATDC induces an invasive switch in KRAS-induced pancreatic tumorigenesis
Wang, L., Yang, H., Abel, E. V., Ney, G. M., Palmbos, P. L., Bednar, F., Zhang, Y., Leflein, J., Waghray, M., Owens, S. R., et al. (2015) · Genes & Development · doi:10.1101/gad.253591.114 · Cited by 76
“%) of KC mice progress to invasive PDA with a long latency ( > 12 mo) (Aguirre et al. 2003; Hingorani et al. 2003, 2005).”
Metadata
- Authors
- Aguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., Redston, M. S., & DePinho, R. A.
- Affiliations
- Harvard University (US)
- Abramson Cancer Center (US)
- Brigham and Women's Hospital (US)
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2003-01-01
- Volume
- 17
- Issue
- 24
- Pages
- 3112-3126
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- PMC
- PMC305262
- OpenAlex
- W2126663928
- Cited by
- 1,033
- References
- 84
- Citations by year
- 2026: 16 · 2025: 27 · 2024: 38 · 2023: 34 · 2022: 40 · 2021: 67 · 2020: 46 · 2019: 45 · 2018: 46 · 2017: 55 · 2016: 49 · 2015: 63 · 2014: 69 · 2013: 67 · 2012: 53
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Genes & Development (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Cancer Society
- Lustgarten Foundation
- Dana-Farber Cancer Institute
- Barr Foundation
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- pancreatic ductal adenocarcinoma, KRAS G12D, Ink4a/Arf, tumor suppressor inactivation, pancreatic intraepithelial neoplasia, premalignant pancreatic lesions, metastasis, mouse tumor model, tumor progression, stromal cell proliferation
- MeSH terms
- Animals, Fibroblasts, Humans, Mice, Transgenic, Pancreatic Neoplasms, Proto-Oncogene Proteins, Genes, ras, Tumor Cells, Cultured, Viral Proteins, Tumor Suppressor Protein p53, Mice, Knockout, Integrases, Cyclin-Dependent Kinase Inhibitor p16, Carcinoma, Pancreatic Ductal, Tumor Suppressor Protein p14ARF, Vascular Endothelial Growth Factor A, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.